Capricor Therapeutics Faces Class Action Over Misleading Efficacy Claims for Deramiocel

Capricor Therapeutics Faces Legal Scrutiny Over Alleged Misleading Drug Efficacy Claims

Capricor Therapeutics, Inc. is currently embroiled in legal challenges following allegations of misleading statements regarding its lead drug candidate, deramiocel, which targets cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The Rosen Law Firm and The Gross Law Firm are actively encouraging investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, to participate in a class action lawsuit. This lawsuit stems from claims that Capricor's management provided overly optimistic forecasts about the drug's potential to secure a Biologics License Application (BLA) from the FDA while withholding critical information about adverse findings related to the drug's safety and efficacy derived from the Phase 2 HOPE-2 trial.

The legal complaint asserts that during the class action period, Capricor representatives failed to disclose significant negative data from the HOPE-2 trial, which could have impacted investors’ decisions. Instead, the company purportedly painted a picture of confidence regarding the FDA's approval process for deramiocel. This situation escalated dramatically when, on July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of the drug's effectiveness and unresolved concerns in the Chemistry, Manufacturing, and Controls (CMC) section. The announcement triggered a significant decline in Capricor's stock price, underscoring the potential ramifications of the alleged misrepresentation.

As the deadline for potential lead plaintiffs approaches on September 15, 2025, affected investors are being urged to act swiftly to join the class action. Both law firms emphasize that participation in the lawsuit carries no upfront costs, allowing investors to pursue compensation without financial risk. This legal action not only aims to hold Capricor accountable for its alleged misleading practices but also highlights the importance of transparency and integrity in the biopharmaceutical industry, particularly in the context of life-altering treatments for serious health conditions like DMD.

In addition to the ongoing legal proceedings, Capricor's situation raises broader concerns about the communication practices within biotech companies. Transparency in clinical trial results and regulatory interactions is critical for maintaining investor confidence and ensuring ethical standards in drug development. As this case unfolds, it serves as a reminder of the vigilance required from both investors and regulatory bodies in overseeing the integrity of pharmaceutical advancements.

The Gross Law Firm has also issued communications to shareholders, reinforcing the message that participation in the class action is an opportunity for those impacted by Capricor's stock decline. This legal initiative seeks to foster accountability while protecting the interests of investors in the fast-paced and often unpredictable biotech sector.